The PD-1/PD-L1 axis and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) have emerged as key targets in the treatment of various cancers, including CRC, demonstrating significant clinical efficacy (19, 20). The gene discussed is CTLA4; the disease is cancer.